Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL179836 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6544499 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL4030100 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL466183 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6672099 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6689206 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL19031792 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL7340062 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL26730 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL1828034 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 54099 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026102415-A1 | MICROBIAL BIOMARKERS OF CANINE IDIOPATHIC EPILEPSY | MARS, INCORPORATED (US) | 2026-05-15 | — | — | WO | claimed |
| CN-122031677-A | Leptin receptor agonist antibodies for the treatment of metabolic dysfunction or hypoleptinemia | 瑞泽恩制药公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122031502-A | Application of BCAA inhibitor in preparation of medicines for treating mutant leukemia | 中国医学科学院北京协和医院 | 2026-05-15 | — | — | CN | claimed |
| EP-4741421-A1 | FAB-ARM EXCHANGE-PREVENTING FC VARIANTS FROM WHICH EFFECTOR FUNCTIONS ARE REMOVED | Korea University Research and Business Foundation (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-0458751-A1 | Delivery system for cyclic amino acids with improved taste, texture and compressibility | WARNER-LAMBERT COMPANY (US) | 1991-11-27 | — | — | EP | claimed |
| US-5068413-A | Process for the preparation of cyclic amino acids and intermediates useful in the process | GODECKE AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | claimed |
| EP-0446570-A2 | Gabapentin and its derivatives for treating neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | claimed |
| US-5025035-A | Administering antidepressants | WARNER-LAMBERT COMPANY (US) | 1991-06-18 | — | — | US | claimed |
| EP-0414274-A2 | Process for the preparation of 1 aminomethyl-1.cyclohexanacetic acid | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-02-27 | — | — | EP | claimed |
| EP-0414262-A2 | Process for the preparation of cyclic amino anticonvulsant compounds | WARNER-LAMBERT COMPANY (US) | 1991-02-27 | — | — | EP | claimed |
| US-4960931-A | Anticonvulsants | WARNER-LAMBERT COMPANY (US) | 1990-10-02 | — | — | US | claimed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | claimed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | claimed |